These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 23213621)

  • 1. Importance of the brain Angiotensin system in Parkinson's disease.
    Wright JW; Harding JW
    Parkinsons Dis; 2012; 2012():860923. PubMed ID: 23213621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases.
    Wright JW; Kawas LH; Harding JW
    Prog Neurobiol; 2015 Feb; 125():26-46. PubMed ID: 25455861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
    Shin E; Rogers JT; Devoto P; Björklund A; Carta M
    Exp Neurol; 2014 Jul; 257():25-38. PubMed ID: 24747357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nicotine and Nicotinic Receptor Drugs: Potential for Parkinson's Disease and Drug-Induced Movement Disorders.
    Quik M; Bordia T; Zhang D; Perez XA
    Int Rev Neurobiol; 2015; 124():247-71. PubMed ID: 26472532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cav1.3 channels control D2-autoreceptor responses via NCS-1 in substantia nigra dopamine neurons.
    Dragicevic E; Poetschke C; Duda J; Schlaudraff F; Lammel S; Schiemann J; Fauler M; Hetzel A; Watanabe M; Lujan R; Malenka RC; Striessnig J; Liss B
    Brain; 2014 Aug; 137(Pt 8):2287-302. PubMed ID: 24934288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expanding the repertoire of L-DOPA's actions: A comprehensive review of its functional neurochemistry.
    De Deurwaerdère P; Di Giovanni G; Millan MJ
    Prog Neurobiol; 2017 Apr; 151():57-100. PubMed ID: 27389773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post mortem studies in Parkinson's disease--is it possible to detect brain areas for specific symptoms?
    Jellinger KA
    J Neural Transm Suppl; 1999; 56():1-29. PubMed ID: 10370901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levodopa-loaded nanoparticles for the treatment of Parkinson's disease.
    van Vliet EF; Knol MJ; Schiffelers RM; Caiazzo M; Fens MHAM
    J Control Release; 2023 Aug; 360():212-224. PubMed ID: 37343725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. l-3,4-dihydroxyphenylalanine (l-DOPA) modulates brain iron, dopaminergic neurodegeneration and motor dysfunction in iron overload and mutant alpha-synuclein mouse models of Parkinson's disease.
    Billings JL; Gordon SL; Rawling T; Doble PA; Bush AI; Adlard PA; Finkelstein DI; Hare DJ
    J Neurochem; 2019 Jul; 150(1):88-106. PubMed ID: 30716176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Noradrenaline and Parkinson's disease.
    Delaville C; Deurwaerdère PD; Benazzouz A
    Front Syst Neurosci; 2011; 5():31. PubMed ID: 21647359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
    During MJ; Kaplitt MG; Stern MB; Eidelberg D
    Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RGS Proteins as Critical Regulators of Motor Function and Their Implications in Parkinson's Disease.
    Ahlers-Dannen KE; Spicer MM; Fisher RA
    Mol Pharmacol; 2020 Dec; 98(6):730-738. PubMed ID: 32015009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interactions Between the Serotonergic and Other Neurotransmitter Systems in the Basal Ganglia: Role in Parkinson's Disease and Adverse Effects of L-DOPA.
    Muñoz A; Lopez-Lopez A; Labandeira CM; Labandeira-Garcia JL
    Front Neuroanat; 2020; 14():26. PubMed ID: 32581728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repulsive Guidance Molecule a (RGMa) Induces Neuropathological and Behavioral Changes That Closely Resemble Parkinson's Disease.
    Korecka JA; Moloney EB; Eggers R; Hobo B; Scheffer S; Ras-Verloop N; Pasterkamp RJ; Swaab DF; Smit AB; van Kesteren RE; Bossers K; Verhaagen J
    J Neurosci; 2017 Sep; 37(39):9361-9379. PubMed ID: 28842419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives.
    Sarkar S; Raymick J; Imam S
    Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27338353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological approaches to disease-modifying therapies in Parkinson's disease.
    O'Neill MJ; Siemers ER
    Expert Rev Neurother; 2002 Nov; 2(6):819-34. PubMed ID: 19810916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exercise-Induced Neuroprotection and Recovery of Motor Function in Animal Models of Parkinson's Disease.
    Palasz E; Niewiadomski W; Gasiorowska A; Wysocka A; Stepniewska A; Niewiadomska G
    Front Neurol; 2019; 10():1143. PubMed ID: 31736859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Animal Models of Autosomal Recessive Parkinsonism.
    Bastioli G; Regoni M; Cazzaniga F; De Luca CMG; Bistaffa E; Zanetti L; Moda F; Valtorta F; Sassone J
    Biomedicines; 2021 Jul; 9(7):. PubMed ID: 34356877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glutathione
    Jewett M; Dickson E; Brolin K; Negrini M; Jimenez-Ferrer I; Swanberg M
    Front Neurol; 2018; 9():222. PubMed ID: 29681884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parkinson's disease: Autoimmunity and neuroinflammation.
    De Virgilio A; Greco A; Fabbrini G; Inghilleri M; Rizzo MI; Gallo A; Conte M; Rosato C; Ciniglio Appiani M; de Vincentiis M
    Autoimmun Rev; 2016 Oct; 15(10):1005-11. PubMed ID: 27497913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.